Tuesday 20 June 2017

President and CEO’s report of BioLargo 2017 Annual Stockholders’ Meeting

Dear BioLargo Stockholders,

We had a great meeting yesterday (June 19th) at our corporate offices in Westminster California. If you were unable to attend, we missed you and we encourage you to attend in the future. Of course, we also encourage you to reach out to us anytime to discuss our status and progress. It was so good to reconnect with old friends and share our team’s enthusiasm for BioLargo and our mission to make life better. 

The business of the meeting was successfully accomplished. All recommendations presented to the stockholders were approved. During a discussion of business progress, we provided insights about a series of important commercial milestones, and helped explain why we believe the future remains so bright for BioLargo. Here are a few highlights:
  1.  Jack B. “Jay” Strommen has officially joined our Board of Directors . He plays a critical role with BioLargo as an investor, partner, and financier of our subsidiary Clyra Medical Technologies. He is a winner and a strong addition to our team, and on behalf of the company we thank him for his hard work. 
  2. We want to take a moment to thank Gary Cox for his years of dedicated service as a Board Member at BioLargo that ended yesterday. We look forward to pursuing new business relationships together in the future. 
  3. We reviewed our presentation given at the 7th Annual LD Micro Invitational conference on June 6, 2017 (linked here), which provided a comprehensive overview of our progress, our milestones, and our near term and long term goals. 
  4. We shared the news (linked here) about our increasing sales of our CupriDyne Clean Industrial Odor Control products,  nd that we expect these sales to continue to increase due to the very recent execution of “National Purchasing Agreements” with two of the top 10 waste handling companies in the industry, as previously announced, providing us vendor status that allows us to sell to the local facilities of these large companies. We also shared new information that we have just entered into a similar contractual relationship with another top industry member. We are now servicing three of the top 10 companies in the waste handling industry. These agreements demonstrate that we are breaking through the significant barriers-to-entry for this market, and are a testimony to the now-recognized superior quality of our products, as well as the continuing commitment of the team at our subsidiary Odor-No-More, Inc. to support these very important customers. As our satisfied customers say, “Finally, an industrial odor control product that actually works”. Stay tuned for more information as we advance sales! 
  5. We enjoyed an update from Mr. Steve Harrison, President of our subsidiary Clyra Medical Technologies, on his plan to file a 510(k) application with the FDA very soon. With the support of a $1 million investment from the Strommen family made over the past year, we were able to develop an advanced wound care product for topical use on chronic infected wounds, and a dental product that can help patients avoid post-surgical infections. We believe these two products set the stage to build a portfolio of products to serve these important markets. Mr. Harrison reported that the first public presentation about our products will be made later this week at the Annual Wound Healing: Science and Industry Conference (WoundHSI), sponsored by the Peter Sheehan Diabetes Care Foundation (http://www.woundhsi.org). Our products will be highlighted in a presentation by a leading professional in the field, Dr. Brock A. Liden, DPM, titled Anti-Infective and Biofilm Therapy. 
  6. We updated the attendees on the advancing discussions with potential engineering scale-up partners, potential commercial partners, and public funding sources for our AOS clean water technology. As you may recall, we have proven the science behind the AOS, and have developed its water disinfection and decontamination thoroughly in the lab. We are now heading from the “Alpha” prototype to a “Beta” prototype, and subsequently to commercialization. The science of this technology is advancing and gaining international acclaim, and we look forward to sharing more details as we prepare for our 3rd annual technical symposium in August.
Before I close, I want to take a moment to remember one our original team members, Mr. Jeffrey Wallace, who recently passed away. Jeff was critical part of the early days of organizing BioLargo into what it has become today. He was a GREAT man that invested his life serving others. As a man of integrity, he mentored more than 50 Eagle Scouts in the Boy Scouts of America program and he left a lasting mark in this world for all things good and right. We will miss Jeff and pray for his family in their loss. Amen.

2017 is the break-through year for BioLargo and we are thankful for your continued support. 

Stay tuned as we march forward in our mission to make life better!

Dennis P. Calvert
President & CEO
BioLargo, Inc.
June 20, 2017

#GoBioLargo #GoOdor-no-more 

Cautionary note regarding forward-looking statements.

All statements, other than statements of historical fact, included in this correspondence regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management are forward-looking statements. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that the expectations underlying our forward-looking statements are reasonable, these expectations may prove to be incorrect, and all of these statements are subject to risks and uncertainties. Therefore, you should not place undue reliance on our forward-looking statements. We have included important risks and uncertainties in the cautionary statements included in our annual report on Form 10-K, particularly the section titled “Risk Factors”, incorporated by reference herein. We believe these risks and uncertainties could cause actual results or events to differ materially from the forward-looking statements that we make. Should one or more of these risks and uncertainties materialize, or should underlying assumptions, projections or expectations prove incorrect, actual results, performance or financial condition may vary materially and adversely from those anticipated, estimated or expected. Our forward-looking statements do not reflect the potential impact of future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not assume any obligation to update any of the forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law. In the light of these risks and uncertainties, the forward-looking events and circumstances discussed in this correspondence may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. Any forward-looking statement made by us in this correspondence is based only on information currently available to us and speaks only as of the date on which it is made.

No comments:

Post a Comment